Patents by Inventor Richard S. Larson
Richard S. Larson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11378576Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents.Type: GrantFiled: February 15, 2019Date of Patent: July 5, 2022Assignees: UNM Rainforest Innovations, National Technology & Engineering Solutions of Sandia, LLCInventors: Richard S. Larson, Brian Hjelle, David C. Brown, Marco Bisoffi, Susan M. Brozik, Darren W. Branch, Thayne L. Edwards, David Wheeler
-
Publication number: 20190242888Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents.Type: ApplicationFiled: February 15, 2019Publication date: August 8, 2019Inventors: Richard S. Larson, Brian Hjelle, Pam R. Hall, David C. Brown, Marco Bisoffi, Susan M. Brozik, Darren W. Branch, Thayne L. Edwards, David Wheeler
-
Patent number: 10031135Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents.Type: GrantFiled: February 4, 2014Date of Patent: July 24, 2018Assignees: STC.UNM, SANDIA CORPORATIONInventors: Richard S. Larson, Brian Hjelle, Pam R. Hall, David C. Brown, Marco Bisoffi, Susan M. Brozik, Darren W. Branch, Thayne L. Edwards, David Wheeler
-
Publication number: 20170184581Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents.Type: ApplicationFiled: January 20, 2017Publication date: June 29, 2017Inventors: Richard S. Larson, Brian Hjelle, Pam R. Hall, David C. Brown, Marco Bisoffi, Susan M. Brozik, Darren W. Branch, Thayne L. Edwards, David Wheeler
-
Patent number: 9546186Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: GrantFiled: August 5, 2014Date of Patent: January 17, 2017Assignee: STC.UNMInventors: Jeffrey P. Norenberg, Richard S. Larson
-
Publication number: 20160324993Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Inventors: Jeffrey P. Norenberg, Richard S. Larson
-
Publication number: 20140341806Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Inventors: Jeffrey P. Norenberg, Richard S. Larson
-
Patent number: 8834838Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: GrantFiled: April 1, 2013Date of Patent: September 16, 2014Assignee: STC.UNMInventors: Jeffrey P. Norenberg, Richard S. Larson
-
Publication number: 20140249042Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents.Type: ApplicationFiled: February 4, 2014Publication date: September 4, 2014Inventors: Richard S. Larson, Brian Hjelle, Pam R. Hall, David C. Brown, Marco Bisoffi, Susan M. Brozik, Darren W. Branch, Thayne L. Edwards, David Wheeler
-
Patent number: 8709791Abstract: A biosensor combining the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In a preferred embodiment, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV). Rapid detection of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, and the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1 The biosensor was able to delect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS).Type: GrantFiled: February 8, 2008Date of Patent: April 29, 2014Assignees: STC.UNM, Sandia National LaboratoriesInventors: Richard S Larson, Brian Hjelle, Pam R Hall, David C Brown, Marco Bisoffi, Susan M Brozik, Darren W Branch, Thayne L Edwards, David Wheeler
-
Patent number: 8435489Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: GrantFiled: December 2, 2011Date of Patent: May 7, 2013Assignee: STC.UNMInventors: Jeffrey P. Norenberg, Richard S. Larson
-
Publication number: 20120070372Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: ApplicationFiled: December 2, 2011Publication date: March 22, 2012Applicant: STC.UNMInventors: Jeffrey P. Norenberg, Richard S. Larson
-
Patent number: 8097237Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.Type: GrantFiled: August 22, 2006Date of Patent: January 17, 2012Assignee: STC.UNMInventors: Jeffrey P. Norenberg, Richard S. Larson
-
Publication number: 20110053139Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents.Type: ApplicationFiled: February 8, 2008Publication date: March 3, 2011Inventors: Richard S. Larson, Brian Hjelle, Pam R. Hall, David C. Brown, Marco Bisoffi, Susan M. Brozik, Darren W. Branch, Thayne L. Edwards, David Wheeler
-
Publication number: 20090208493Abstract: Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed.Type: ApplicationFiled: November 28, 2008Publication date: August 20, 2009Applicant: STC. UNMInventors: Richard S. Larson, Larry A. Sklar, Bruce S. Edwards, Irena D. Ivnitski-Steele, Tudor I. Oprea, Debbie M. Lovato, Hadya M. Khawaja, Stuart S. Winter, Susan M. Young
-
Patent number: 6881747Abstract: The present invention provides a compound and a method of making a compound according to the following formula: where R1 is an alkyl group having 1 to 12 carbons; R2 is a urea group; R3 is an active group, such as fluorescein, a toxin, radiolabel or drug; and R4, R5 and R6 are each independently a halide group.Type: GrantFiled: May 5, 2003Date of Patent: April 19, 2005Assignees: Science & Technology Corporation @UNM, Regents of the University of MinnesotaInventors: Richard S. Larson, Carston R. Wagner
-
Publication number: 20040023929Abstract: The present invention provides a compound and a method of making a compound according to the following formula: 1Type: ApplicationFiled: May 5, 2003Publication date: February 5, 2004Inventors: Richard S. Larson, Carston R. Wagner
-
Patent number: 6649592Abstract: Cyclic peptides inhibit LFA-1 interaction with ICAM-1 and are useful in treatment of hematopoietic neoplasms and in adjunct therapy in prevention of retinoic acid syndrome and diseases involving emigration of leukocytes into organ tissue.Type: GrantFiled: January 14, 2000Date of Patent: November 18, 2003Assignee: Science & Technology Corporation @ UNMInventor: Richard S. Larson
-
Patent number: 6630447Abstract: Cyclic peptides inhibit LFA-1 interaction with ICAM-1 and are useful in treatment of hematopoietic neoplasms and in adjunct therapy in prevention of retinoic acid syndrome and diseases involving emigration of leukocytes into organ tissue.Type: GrantFiled: January 16, 2001Date of Patent: October 7, 2003Assignee: University of New MexicoInventor: Richard S. Larson
-
Publication number: 20010034326Abstract: Cyclic peptides inhibit LFA-1 interaction with ICAM-1 and are useful in treatment of hematopoietic neoplasms and in adjunct therapy in prevention of retinoic acid syndrome and diseases involving emigration of leukocytes into organ tissue.Type: ApplicationFiled: January 16, 2001Publication date: October 25, 2001Applicant: University of New Mexico Science & Technology CorporationInventor: Richard S. Larson